CN1358094A - 用mek抑制剂治疗慢性疼痛的方法 - Google Patents

用mek抑制剂治疗慢性疼痛的方法 Download PDF

Info

Publication number
CN1358094A
CN1358094A CN00809478A CN00809478A CN1358094A CN 1358094 A CN1358094 A CN 1358094A CN 00809478 A CN00809478 A CN 00809478A CN 00809478 A CN00809478 A CN 00809478A CN 1358094 A CN1358094 A CN 1358094A
Authority
CN
China
Prior art keywords
methyl
fluoro
iodo
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00809478A
Other languages
English (en)
Chinese (zh)
Inventor
S·D·巴瑞特
A·J·布里德格斯
H·泰克
A·迪克森
K·利
R·D·皮诺可
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1358094A publication Critical patent/CN1358094A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CN00809478A 1999-07-16 2000-07-05 用mek抑制剂治疗慢性疼痛的方法 Pending CN1358094A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14441899P 1999-07-16 1999-07-16
US60/144,418 1999-07-16

Publications (1)

Publication Number Publication Date
CN1358094A true CN1358094A (zh) 2002-07-10

Family

ID=22508500

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00809478A Pending CN1358094A (zh) 1999-07-16 2000-07-05 用mek抑制剂治疗慢性疼痛的方法

Country Status (13)

Country Link
EP (1) EP1202731A2 (fr)
JP (1) JP2003504398A (fr)
KR (1) KR20020015376A (fr)
CN (1) CN1358094A (fr)
AU (1) AU6068600A (fr)
CA (1) CA2377092A1 (fr)
CO (1) CO5190704A1 (fr)
HU (1) HUP0202319A3 (fr)
IL (1) IL147150A0 (fr)
PE (1) PE20010546A1 (fr)
PL (1) PL352835A1 (fr)
WO (1) WO2001005390A2 (fr)
ZA (1) ZA200109906B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101486682B (zh) * 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
CN104774188A (zh) * 2014-01-15 2015-07-15 江苏恒瑞医药股份有限公司 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CN109336824A (zh) * 2012-10-19 2019-02-15 诺华股份有限公司 Mek抑制剂的制备和包含mek抑制剂的制剂
CN114788867A (zh) * 2022-04-24 2022-07-26 天津医科大学总医院 Map2k1作为化疗后神经痛的治疗靶点的应用

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
WO2002102232A2 (fr) * 2001-06-14 2002-12-27 The Regents Of The University Of California Nouvelle voie de signalisation destinee a la production de douleur inflammatoire et de neuropathie
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1482944A4 (fr) * 2002-03-13 2006-04-19 Array Biopharma Inc Derives de benzimidazole n3 alkyles servant d'inhibiteurs de mek
GB0213383D0 (en) * 2002-06-11 2002-07-24 Cambridge Biotechnology Ltd Therapeutic conditions
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
CA2532067C (fr) 2003-07-24 2010-12-21 Stephen Douglas Barrett Benzimidazoles n-methyle-substitues
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
PT1673349E (pt) 2003-09-22 2010-09-28 S Bio Pte Ltd Derivados benzimidazole: preparação e aplicações farmacêuticas
CA2546353A1 (fr) 2003-11-19 2005-06-09 Array Biopharma Inc. Inhibiteurs bicycliques de mek, et leurs procedes d'utilisation
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2546754A1 (fr) 2003-11-21 2005-06-09 Array Biopharma Inc. Inhibiteurs de la proteine kinase akt
SG177981A1 (en) 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
US8039637B2 (en) 2005-06-23 2011-10-18 Array Biopharma Inc. Process for preparing benzimidazole compounds
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2049500B1 (fr) 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la protéine kinase akt
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
WO2008076415A1 (fr) 2006-12-14 2008-06-26 Exelixis, Inc. Procédés d'utilisation d'inhibiteurs de mek
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
CN101918373B (zh) 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
AU2008343065B2 (en) 2007-12-19 2012-04-05 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
PT2231662E (pt) 2007-12-19 2011-09-12 Genentech Inc 8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios
NZ586575A (en) 2007-12-21 2012-03-30 Genentech Inc Azaindolizines and methods of use
NZ586346A (en) 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
US8993630B2 (en) 2008-11-10 2015-03-31 Bayer Intellectual Property Gmbh Substituted sulphonamido phenoxybenzamides
US20120263714A1 (en) 2009-10-21 2012-10-18 Bayer Intellectual Property Gmbh Substituted halophenoxybenzamide derivatives
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
EP2491015A1 (fr) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Benzosulfonamides substitués
CN103282351A (zh) 2010-10-29 2013-09-04 拜耳知识产权有限责任公司 取代的苯氧基吡啶
TR201815685T4 (tr) 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
ES2396764B1 (es) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
WO2013096744A1 (fr) 2011-12-21 2013-06-27 Novira Therapeutics, Inc. Agents antiviraux de l'hépatite b
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
EA038942B1 (ru) 2012-08-28 2021-11-12 Янссен Сайенсиз Айрлэнд Юси Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
MA38085B1 (fr) 2012-10-12 2018-11-30 Exelixis Inc Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
TWI651300B (zh) 2013-05-17 2019-02-21 健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
DK3024819T3 (en) 2013-07-25 2018-06-06 Janssen Sciences Ireland Uc GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
WO2015118057A1 (fr) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Dérivés de sulfamoylpyrrolamide et leur utilisation en tant que médicaments pour le traitement de l'hépatite b
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
EP3271019A1 (fr) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Dérivés d'azocane et d'azonane, et méthodes de traitement d'infections provoquées par le virus de l'hépatite b
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
HK1259410A1 (zh) 2015-09-29 2019-11-29 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
CA3090125A1 (fr) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Schema posologique de modulateur d'assemblage de capside
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MA55879A (fr) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
CN110981819B (zh) * 2019-12-24 2022-07-01 广西师范大学 一种喹喔啉类信号通路抑制剂及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037881A1 (fr) * 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
CA2355470C (fr) * 1999-01-13 2008-09-30 Warner-Lambert Company Les benzoheterocycles et leur utilisation comme inhibiteurs de mek

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101486682B (zh) * 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
CN109336824A (zh) * 2012-10-19 2019-02-15 诺华股份有限公司 Mek抑制剂的制备和包含mek抑制剂的制剂
CN104774188A (zh) * 2014-01-15 2015-07-15 江苏恒瑞医药股份有限公司 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CN104774188B (zh) * 2014-01-15 2019-10-11 江苏恒瑞医药股份有限公司 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CN114788867A (zh) * 2022-04-24 2022-07-26 天津医科大学总医院 Map2k1作为化疗后神经痛的治疗靶点的应用

Also Published As

Publication number Publication date
EP1202731A2 (fr) 2002-05-08
PL352835A1 (en) 2003-09-08
WO2001005390A3 (fr) 2001-05-17
JP2003504398A (ja) 2003-02-04
AU6068600A (en) 2001-02-05
HUP0202319A3 (en) 2004-12-28
CO5190704A1 (es) 2002-08-29
CA2377092A1 (fr) 2001-01-25
HUP0202319A2 (en) 2002-10-28
KR20020015376A (ko) 2002-02-27
PE20010546A1 (es) 2001-06-04
IL147150A0 (en) 2002-08-14
WO2001005390A2 (fr) 2001-01-25
ZA200109906B (en) 2003-05-28

Similar Documents

Publication Publication Date Title
CN1358094A (zh) 用mek抑制剂治疗慢性疼痛的方法
CN1094490C (zh) 作为血清素拮抗剂的喹诺－2(1h)－酮衍生物
CN1287487A (zh) 氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1028104C (zh) 制备喹诺酮衍生物的方法
CN1116288C (zh) 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
CN1210268C (zh) ((环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
CN1261098C (zh) p38－α激酶的抑制剂
CN1520293A (zh) 作为抗糖尿病药物的3-氟-吡咯烷类
CN1309711C (zh) 3－酰氨基－1,2－苯并异噁唑衍生物、其制备方法及应用
CN1230174C (zh) 治疗偏头痛的选择性iGluR5受体拮抗剂
CN102458407B (zh) 用作单酰甘油脂肪酶抑制剂的杂芳族和芳族哌嗪基氮杂环丁基酰胺
CN1589264A (zh) 用于治疗恶性肿瘤的方法
CN1496980A (zh) 具有抗哮喘、抗过敏和免疫抑制/免疫调节作用的n-取代的吲哚-3-乙醛酰胺类化合物
CN1255493A (zh) 新的二氢和四氢喹啉化合物,其制备方法及其药物组合物
CN85107020A (zh) 烷基亚磺酰胺基苯基烷基胺的制备方法
CN1234797A (zh) N－取代的氮杂环化合物
JP7143296B2 (ja) ピペリジン－２，６－ジオン誘導体及び潰瘍性結腸炎の治療
CN1271354A (zh) 具有神经原活性的化合物
CN1032534C (zh) 二氨基三氟甲基吡啶衍生物的制备方法
CN1062729A (zh) 可用作血管紧张肽转化酶抑制剂的含氨基和硝基的三环新化合物
CN1336915A (zh) N－杂环羧酸或羧酸等排物的脲和氨基羧酸酯
CN1278809A (zh) 取代的苯并二氢吡喃衍生物
CN1301265A (zh) 新的用作金属蛋白酶抑制剂的取代的芳基异羟肟酸
CN1079789C (zh) 新的羟肟酸衍生物,包含它们的药物组合物及其制法
CN1299346A (zh) N－杂环羧酸或羧酸等排物的脲和氨基羧酸酯

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1047233

Country of ref document: HK